NBRV News and Press, Nabriva Therapeutics plc From 03/12/19

Nabriva Therapeutics (NASDAQ: NBRV ): FY GAAP EPS of -$2.26. More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

- Two PDUFA dates in 2019: April 30, 2019 for CONTEPO and August 19, 2019 for Lefamulin - - Company preparing for potential commercialization of two first-in-class antibiotics,  Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland, March 12,...

The FDA has accepted Nabriva Therapeutics' (NASDAQ: NBRV ) New Drug Applications (NDAs) for both the intravenous (IV) and oral formulations of lefamulin, a semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia (CABP). More news on: Nabriva T...

DUBLIN, Ireland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administrat...

ProMetic Life Sciences ( OTCQX:PFSCF ) upgraded to Sector Perform at National Bank. More news on: ProMetic Life Sciences Inc., Selecta Biosciences, Nabriva Therapeutics, Healthcare stocks news, Stocks on the move, , Read more ...

Nabriva Therapeutics (NASDAQ: NBRV ): Q2 EPS of -$0.44 beats by $0.04 . More news on: Nabriva Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...

- Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - - New Drug Application submissions expected in Q4 2018 - DUBLIN, Ireland, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Nabriva Thera...